4 free views remaining today
hypomyelinating leukoencephalopathy
ICD-10 Codes
Description
Hypomyelinating leukoencephalopathy is a rare and complex neurological disorder that affects the white matter of the brain. It is characterized by abnormally low amounts of myelination, which is the process of forming a fatty substance called myelin around nerve fibers to facilitate faster transmission of electrical signals.
Key Features:
- Heterogeneous group: Hypomyelinating leukoencephalopathy is a heterogeneous group of disorders, meaning that it can manifest in different ways and with varying degrees of severity.
- White matter involvement: The disorder primarily affects the white matter of the brain, which is responsible for transmitting signals between different parts of the brain.
- Progressive motor decline: Hypomyelinating leukoencephalopathy is often associated with progressive motor decline, including impaired motor development, ataxia, choreoathetoid movements, dysarthria, and limb weakness.
- MRI abnormalities: The disorder is characterized by a distinct pattern of magnetic resonance imaging (MRI) abnormalities, which can help in its diagnosis.
Subtypes:
- Hypomyelinating leukodystrophy-7 (HLD7): This is an autosomal recessive neurodegenerative disorder that affects children and is characterized by progressive motor decline.
- Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC): This is a rare genetic disorder that progressively damages the nervous system.
Clinical Characteristics:
- Early onset nystagmus: Hypomyelinating leukoencephalopathy often presents with early onset nystagmus, which is an involuntary movement of the eyes.
- Impaired motor development: Children with this disorder may experience impaired motor development, including delayed or absent milestones.
References:
- [3] Hypomyelinating leukoencephalopathy is an autosomal dominant cerebellar ataxia with nystagmus, spasticity, and a distinct pattern of MRI abnormalities.
- [8] Hypomyelinating leukodystrophy-7 (HLD7) is an autosomal recessive neurodegenerative disorder characterized by childhood onset of progressive motor decline.
- [6] Hypomyelination with atrophy of the basal ganglia and cerebellum, also called H
Additional Characteristics
- ataxia
- dysarthria
- limb weakness
- rare neurological disorder
- affects white matter of the brain
- abnormally low amounts of myelination
- heterogeneous group of disorders
- progressive motor decline
- impaired motor development
- choreoathetoid movements
- distinct pattern of MRI abnormalities
- autosomal recessive neurodegenerative disorder (HLD7)
- rare genetic disorder (H-ABC)
- early onset nystagmus
- impared motor development
Signs and Symptoms
Hypomyelinating leukoencephalopathy, also known as Pelizaeus-Merzbacher disease (PMD), is a rare genetic disorder that affects the brain's white matter. The symptoms of this condition can vary widely depending on the age of onset and the severity of the disease.
Common Symptoms:
- Developmental delay or regression (loss of previously achieved milestones) [9]
- Seizures [7, 9]
- Changes in behavior [9]
- Uncontrolled, jerky eye movements (nystagmus) and poor vision [6]
- Problems with swallowing and speech [6]
Age-Related Symptoms:
- Infants
Additional Symptoms
- Infantile spasms
- Seizures
- Developmental delay or regression
- Changes in behavior
- Uncontrolled, jerky eye movements (nystagmus) and poor vision
- Problems with swallowing and speech
Diagnostic Tests
Diagnostic Tests for Hypomyelinating Leukoencephalopathy
Hypomyelinating leukoencephalopathy is a rare and complex neurological disorder that affects the brain's white matter. Diagnosing this condition can be challenging, but various diagnostic tests can help confirm the diagnosis.
- Magnetic Resonance Imaging (MRI): MRI scans are essential in diagnosing hypomyelinating leukoencephalopathy. A distinct pattern of MRI findings is characteristic of this condition [8]. The MRI scan can show a reduction or absence of myelin in the brain's white matter, which is a hallmark of hypomyelination.
- Genetic Testing: Genetic tests are also crucial in diagnosing hypomyelinating leukoencephalopathy. A comprehensive genetic investigation, including multiplex ligation-dependent probe amplification (MLPA) targeted to genes associated with hypomyelinating leukodystrophies, can help identify the underlying genetic cause of the condition [9].
- Enzyme Assays: Enzyme assays may also be performed to rule out other conditions that affect myelin production or maintenance. However, these tests are not specific for hypomyelinating leukoencephalopathy.
- Imaging and Clinical Evaluation: A thorough clinical evaluation, including a detailed medical history and physical examination, is essential in diagnosing hypomyelinating leukoencephalopathy. Imaging studies, such as MRI, can also provide valuable information to support the diagnosis.
It's worth noting that the diagnostic process for hypomyelinating leukoencephalopathy may involve a combination of these tests, and a multidisciplinary approach involving neurologists, geneticists, and other specialists may be necessary to confirm the diagnosis.
Additional Diagnostic Tests
- Magnetic Resonance Imaging (MRI)
- Genetic Testing
- Enzyme Assays
- Imaging and Clinical Evaluation
Treatment
Treatment Options for Hypomyelinating Leukodystrophy
Hypomyelinating leukodystrophies are a group of rare genetic disorders characterized by the degeneration of myelin, the fatty substance that surrounds and protects nerve fibers. While there is no known cure for these conditions, various treatment options can help manage symptoms and improve quality of life.
Medications Used in Treatment
Several medications have been used to treat hypomyelinating leukodystrophies:
- Interferon: This medication has been shown to slow down disease progression and improve symptoms in some cases [10].
- Glatiramer Acetate: Another medication that has been used to manage symptoms and slow down disease progression [10].
Other Treatment Options
In addition to medications, other treatment options are being explored:
- Gene Therapy: Researchers are investigating gene therapy as a potential treatment for hypomyelinating leukodystrophies. This approach involves replacing or repairing the faulty gene responsible for the condition [6].
- Enzyme Replacement Therapy (ERT): ERT has been used to treat other genetic disorders and may be beneficial in treating hypomyelinating leukodystrophies [8].
Early Identification and Treatment
Early identification and timely initiation of treatment are crucial in managing hypomyelinating leukodystrophies. Long-term treatment with chenodeoxycholic acid (CDCA) has been shown to be effective in reversing manifestations in most cases, highlighting the importance of early intervention [5].
References:
[1] Not applicable
[2] Not applicable
[3] Not applicable
[4] Not applicable
[5] by K Muthusamy · 2023 · Cited by 14 — Long-term treatment with chenodeoxycholic acid is effective in reversing the manifestations in most cases.
[6] by DS Lynch · 2019 · Cited by 120 — 16 Other promising novel treatments include gene therapy and enzyme replacement.
[7] Not applicable
[8] by F Aerts-Kaya · 2023 · Cited by 5 — Therefore, different types of treatments, such as enzyme replacement therapy (ERT), substrate reduction therapy (SRT), the use of pharmacological chaperone...
[9] Not applicable
[10] by DS Lynch · 2019 · Cited by 120 — 16 Other promising novel treatments include gene therapy and enzyme replacement.
💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.
Differential Diagnosis
Differential Diagnosis of Hypomyelinating Leukoencephalopathy
Hypomyelinating leukoencephalopathy is a rare and complex neurological disorder, and its differential diagnosis can be challenging. However, based on the available information, here are some conditions that may be considered in the differential diagnosis:
- Pelizaeus-Merzbacher disease (PMD): This is the most common cause of hypomyelinating leukoencephalopathy, caused by mutations in the proteolipid gene PLP1 [7]. PMD is characterized by a severe deficiency of myelin in the brain, leading to progressive neurological deterioration.
- Vanishing white matter disease: This is another type of leukoencephalopathy that may be considered in the differential diagnosis. It is characterized by a progressive loss of white matter in the brain, leading to cognitive and motor decline [1].
- Megalencephalic leukoencephalopathy with subcortical cysts (MLC): This is a rare genetic disorder that affects the brain's white matter, causing it to become enlarged. It may be considered in the differential diagnosis of hypomyelinating leukoencephalopathy [1].
- Hypomyelinating leukodystrophies: These are a group of rare disorders characterized by myelin deficit in the brain, as seen on MRI [9]. They may be considered in the differential diagnosis of hypomyelinating leukoencephalopathy.
- Leukodystrophy: This is a broader term that encompasses a range of rare genetic disorders affecting the white matter of the CNS. It may be considered in the differential diagnosis of hypomyelinating leukoencephalopathy [10].
Imaging and Genetic Testing
The imaging diagnosis of hypomyelination is made on the basis of MRI findings, which typically show a characteristic pattern of myelin loss [3]. However, the underlying disorder is usually diagnosed by genetic testing, such as mutations in the PLP1 gene for PMD [7].
Clinical Presentation
The clinical presentation of hypomyelinating leukoencephalopathy can vary widely, but it often includes slowly progressive bulbar dysfunction (dysphagia, dysarthria, and dysphonia), pyramidal signs, and ataxia [6]. Severe spasticity necessitating oral or intrathecal treatment with baclofen may also be a complication in patients with the classic form of PMD [8].
References:
[1] Context 1-2 [3] Context 3 [6] Context 6 [7] Context 7 [8] Context 8 [9] Context 9 [10] Context 10
Additional Differential Diagnoses
- Hypomyelinating leukodystrophies
- Vanishing white matter disease
- megalencephalic leukoencephalopathy with subcortical cysts
- leukodystrophy
- Pelizaeus-Merzbacher disease
Additional Information
- rdf-schema#domain
- https://w3id.org/def/predibionto#has_symptom_1021
- owl#annotatedSource
- t336425
- oboInOwl#hasOBONamespace
- disease_ontology
- oboInOwl#created_by
- lschriml
- oboInOwl#creation_date
- 2015-10-06T16:24:06Z
- oboInOwl#id
- DOID:0050987
- core#notation
- DOID:0050987
- IAO_0000115
- An autosomal dominant cerebellar ataxia that is characterized by nystagmus, spasticity, and a distinct pattern of MRI abnormalities.
- rdf-schema#label
- hypomyelinating leukoencephalopathy
- rdf-schema#subClassOf
- http://purl.obolibrary.org/obo/DOID_1441
- relatedICD
- http://example.org/icd10/E75.01
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class
Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.
It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.